AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19178123
Drug: Subcutaneous interferon-beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon-beta-1a (SC IFNb1a) administered three times a week
Trial: 19178123
Drug: Intramuscular interferon-beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon-beta-1a (IM IFNb1a) administered once a week
Trial: 19178123
Drug: Subcutaneous interferon-beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon-beta-1a (SC IFNb1a)
Trial: 19178123
Drug: Intramuscular interferon-beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon-beta-1a (IM IFNb1a)
Trial: 17705694
Drug: Rosiglitazone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (1 year administration)
Trial: 21777702
Drug: Polypill containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill containing 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and either 12.5 mg hydrochlorothiazide or 50 mg atenolol
Trial: 19396428
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (surgical release of the internal obturator tendon)
Trial: 19396428
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-operative treatment)
Trial: 12823077
Drug: Fluvoxamine CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine CR (100 to 300 mg once daily for 12 weeks)
Trial: 7784236
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (digitalis, diuretics, and vasodilators) for 8.1 +/- 0.7 months (Control)
Trial: 7784236
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus prednisone and azathioprine
Trial: 7784236
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus prednisone and cyclosporine
Trial: 28662153
Drug: Daily physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physiotherapy with progressive knee‐extension strength training (10RM), 3 x 10 repetitions, of the fractured limb using ankle weight cuffs.
Trial: 28662153
Drug: Daily physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physiotherapy without strength training.
Trial: 25844612
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 1.2%/BP 3.75% gel
Trial: 23586591
Drug: Bifonazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole 1% cream for 4 weeks after non-surgical nail ablation with urea 40% paste
Trial: 16881474
Drug: transrectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transrectal lidocaine gel
Trial: 16881474
Drug: quadrant lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: quadrant lidocaine injections
Trial: 16881474
Drug: apex‐only lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apex‐only lidocaine injections
Trial: 25139979
Drug: Parenteral cysteine-HCl
RxNorm normalized name: Cysteine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral cysteine-HCl (CYS group) at 121 mg/kg/d for ≥7 days
Trial: 21712498
Drug: darunavir/ritonavir (600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/ritonavir (600/100 mg twice daily)
Trial: 21712498
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of darunavir/ritonavir and rosuvastatin
Trial: 18279940
Drug: Intermittent Androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Androgen Deprivation (IAD) therapy with bicalutamide 150 mg once daily in on-phases and no therapy in off-phases (Group A)
Trial: 18279940
Drug: Intermittent Androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Androgen Deprivation (IAD) therapy with bicalutamide 150 mg once daily in on-phases and etoricoxib 60 mg once daily in off-phases (Group B)
Trial: 11776031
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with cyclophosphamide 300 mg/m2, vincristine 1.4 mg/m2, adriamycin 50 mg/m2, lomustine 50 mg/m2 on day 1, and cisplatin 20 mg/m2 on days 1-5, repeated every 4-6 weeks for 4 cycles, followed by oral ftorafur (FT-207) 600-900 mg/d for 1 year
Trial: 11776031
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with cyclophosphamide, vincristine, adriamycin, lomustine, and cisplatin
Trial: 8858224
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (serum free insulin approximately 480 pmol/l)
Trial: 8858224
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (physiological NaCl solution)
Trial: 8858224
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of insulin infusion vs saline infusion
Trial: 1634647
Drug: Nicoderm (nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicoderm (nicotine transdermal system) 14 mg/day applied to upper back
Trial: 1634647
Drug: Nicoderm (nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicoderm (nicotine transdermal system) 14 mg/day applied to upper outer arm
Trial: 1634647
Drug: Nicoderm (nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicoderm (nicotine transdermal system) 14 mg/day applied to upper chest
Trial: 24973281
Drug: Lumacaftor 200
RxNorm normalized name: lumacaftor 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor 200 mg once daily and ivacaftor 250 mg every 12 h for 14 days followed by 7 days of ivacaftor or 21 days of placebo
Trial: 24973281
Drug: Lumacaftor 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor 400 mg once daily
Trial: 24973281
Drug: Lumacaftor 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor 600 mg once daily
Trial: 24973281
Drug: Lumacaftor 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor 400 mg every 12 h
Trial: 19229449
Drug: Low-frequency repetitive
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency repetitive transcranial magnetic stimulation (0.5 Hz, 15 min/session, twice a day for 2 weeks)
Trial: 17373173
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide (BP) 9% cleanser daily, clindamycin 1% foam daily, doxycycline 100 mg twice daily
Trial: 17373173
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide (BP) 9% cleanser daily, doxycycline 100 mg twice daily without clindamycin 1% foam
Trial: 9592633
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IGF‐I (rhIGF‐I) therapy (40‐80 micrograms/kg/day)
Trial: 20019909
Drug: Cadmium exposure
RxNorm normalized name: cadmium
DrugBank: Cadmium (DB14085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadmium exposure (measured as blood cadmium concentration of 0.21 microg/L)
Trial: 9726716
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with nebulized 2.5 mg salbutamol plus 0.5 mg ipratropium bromide
Trial: 9726716
Drug: Nebulized 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized 2.5 mg salbutamol alone
Trial: 2493044
Drug: Theophylline-terfenadine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline-terfenadine combination
Trial: 17611232
Drug: Oral co-amoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co-amoxiclav (50 mg/kg/day in three doses for 10 days)
Trial: 17611232
Drug: Parenteral ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral ceftriaxone (50 mg/kg/day in a single parenteral dose for three days) followed by oral co-amoxiclav (50 mg/kg/day in three divided doses for seven days)
Trial: 17611232
Drug: Parenteral ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral ceftriaxone followed by oral co-amoxiclav
Trial: 12162764
Drug: Cisplatin/epinephrine injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/epinephrine injectable gel
Trial: 1674853
Drug: Ipsapirone, 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone, 0.3 mg/kg
Trial: 6758747
Drug: Sodium Heparin
RxNorm normalized name: Heparin Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Heparin
Trial: 28805045
Drug: IV golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV golimumab at 2 mg/kg
Trial: 19630068
Drug: Interpersonal Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal Therapy
Trial: 19630068
Drug: Cognitive factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive factor estimated cost and treatment
Trial: 19630068
Drug: Pre-treatment use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment use of anxiolytics
Trial: 17645261
Drug: Combined TCM
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined TCM and western medicine
Trial: 16286871
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of whey and caseinate proteins (PROT)
Trial: 9862605
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to alternative medication
Trial: 2296932
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg daily oral folic acid supplement (F group)
Trial: 6968153
Drug: Anticoagulant or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant or antiplatelet therapy
Trial: 6968153
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antithrombotic therapy)
Trial: 31055526
Drug: Increased level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased level of blood medium-weight molecules (MWM254)
Trial: 31055526
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hypoleptinemia with severe endogenous intoxication
Trial: 16365887
Drug: ThermaCool device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThermaCool device (one treatment)
Trial: 16365887
Drug: ThermaCool device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThermaCool device (two treatments)
Trial: 16365887
Drug: ThermaCool device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThermaCool device (one and two treatments)
Trial: 2242492
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection for the first 6 months, followed by sCT 100 MRC U injected i.m. every other day for the next 6 months
Trial: 358766
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of lidocaine (bolus dose 50 mg followed by infusion 3 mg/min)
Trial: 358766
Drug: QX-572 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QX-572 (600 mg N,N‐bis dimethylammonium chloride) as an i.v. infusion during 30 min or 60 min
Trial: 358766
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard lidocaine therapy)
Trial: 22499718
Drug: Ginseng (G)
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng (G)
Trial: 22499718
Drug: Ginseng +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng + Exercise (G+Ex)
Trial: 19230172
Drug: cilazapril 10
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril 10 mg
Trial: 19230172
Drug: cilazapril 5
RxNorm normalized name: cilazapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril 5 mg
Trial: 9931211
Drug: Oxygen via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen via face mask at 12 l/min (group C)
Trial: 9931211
Drug: Oxygen via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen via nasal prongs at 5 l/min (group B)
Trial: 7844680
Drug: Parenteral L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral L-carnitine supplementation (50 mumol/kg per day)
Trial: 7844680
Drug: Parenteral L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral L-carnitine supplementation
Trial: 2190462
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN), 120 mg once daily
Trial: 2190462
Drug: Nifedipine, 20
RxNorm normalized name: Nifedipine, 20 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 20 mg twice daily
Trial: 20587541
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of UV‐A (25%), UV‐B (5%) and visible light (70%)
Trial: 17624203
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg, adjusted to 25 mg or 100 mg as needed)
Trial: 11228485
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/d for 1 year
Trial: 7846210
Drug: Lorazepam (0.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.0, 0.06, 0.13, 0.25, 0.5 mg; total cumulative dose: 0.94 mg)
Trial: 26437529
Drug: Aromatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatic therapy using menthol
Trial: 21468614
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (500 mg in 20 ml saline)
Trial: 21468614
Drug: Levobupivacaine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine (100 mg in 20 ml 0.5%)
Trial: 21468614
Drug: Lornoxicam (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (8 mg in 20 ml saline)
Trial: 11123496
Drug: Infusion devices
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion devices prepared by pharmacy (5 days)
Trial: 11123496
Drug: Reconstituted drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted drugs by patients (5 days)
Trial: 29154159
Drug: Eye Movement
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Movement Desensitization and Reprocessing therapy (EMDR)
Trial: 28760425
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (60 μg/d as selenious acid added to PN)
Trial: 23731375
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 200 mg per day
Trial: 23731375
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 400 mg per day
Trial: 23731375
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 800 mg per day
Trial: 23731375
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 200 mg per day, 400 mg per day, and 800 mg per day
Trial: 16364710
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement (PRO, Myoplex, EAS, Inc. Golden CO) containing 280 kcal, 42 g protein, 21 g carbohydrate, and 1.5 g fat
Trial: 9457544
Drug: Self-reinforced poly-L-lactide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reinforced poly-L-lactide (SR-PLLA) screws
Trial: 6127963
Drug: Intravenous theophyllamine
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophyllamine (maximal mean plasma concentration of 16.7 +/- 1.21 micrograms/ml)
Trial: 6127963
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline (five inhalations)
Trial: 6127963
Drug: Oral theophylline
RxNorm normalized name: theophylline Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral theophylline (equipotent doses)
Trial: 6127963
Drug: Oral terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline (equipotent doses)
Trial: 31626158
Drug: Magnetophoretic diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetophoretic diclofenac gel delivery using a traveling magnetic field (intensity, 20 mT; frequency, 6.25 Hz; exposure 20 min, 12 sessions)
Trial: 31626158
Drug: Low-frequency pulse
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency pulse magnetotherapy with traveling magnetic field without topical diclofenac therapy
Trial: 17686440
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment with gemcitabine after first-line therapy
Trial: 17686440
Drug: Adding bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adding bevacizumab to standard treatment
Trial: 17686440
Drug: Platinum-based doublet
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based doublet with an additional cytotoxic agent
Trial: 7696057
Drug: Continuous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous propofol and intermittent fentanyl (TIVA) with tracheal tube, neuromuscular blockers
Trial: 7696057
Drug: Continuous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous propofol and intermittent fentanyl (TIVA) with tracheal tube, no neuromuscular blocker (Group 2)
Trial: 7696057
Drug: Continuous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous propofol and intermittent fentanyl (TIVA) with LMA, no neuromuscular blocker (Group 4)
Trial: 7696057
Drug: Continuous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous propofol and intermittent fentanyl (TIVA) with LMA, neuromuscular blockers (Group 3)
Trial: 2654200
Drug: Desipramine 75
RxNorm normalized name: desipramine 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine 75 mg daily
Trial: 31150315
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (3 cycles of fluorouracil, leucovorin, and oxaliplatin) before fluorouracil/oxaliplatin CRT (50.4 Gy)
Trial: 31150315
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy after CRT
Trial: 22151937
Drug: Samphire formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samphire formulations (0.1% serum, 0.05% cream, serum-cream association, 0.5% silicone oil)
Trial: 20175799
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of ascorbic acid and 400 IU of alpha‐tocopherol (treatment group)
Trial: 12515705
Drug: Standard Wedged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Wedged Treatment
Trial: 14767299
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg finasteride daily for 4 years
Trial: 24410738
Drug: SMS text-message
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS text-message intervention (structured programme of clinic appointment, medication pick-up reminders, medication adherence support, and hypertension-related education)
Trial: 17515293
Drug: Demoksil 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demoksil 1 g tablet (test preparation)
Trial: 17515293
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g tablet of the originator product (reference preparation)
Trial: 17688076
Drug: Both test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both test and reference preparations